Summit Therapeu ADR (SMMT)

Jan 30, 2026, 4:30 PM EST - 15 days ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 29, 2026, 7:30 AM EST - 16 days ago

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

Jan 12, 2026, 3:56 PM EST - 4 weeks ago

Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 6:15 AM EST - 4 weeks ago

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

GSK

Jan 12, 2026, 6:00 AM EST - 4 weeks ago

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Jan 6, 2026, 7:30 AM EST - 5 weeks ago

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 9:43 PM EST - 2 months ago

Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 5:13 PM EST - 2 months ago

Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 19, 2025, 4:26 AM EST - 3 months ago

Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying

Nov 18, 2025, 12:38 PM EST - 3 months ago

Summit Therapeutics Inc. (SMMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 11, 2025, 4:11 AM EST - 3 months ago

Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 9:00 AM EST - 3 months ago

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

Nov 4, 2025, 7:00 AM EST - 3 months ago

Summit Therapeutics to Present at Upcoming Investor Conferences

Oct 31, 2025, 7:00 AM EDT - 3 months ago

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Oct 22, 2025, 8:00 AM EDT - 4 months ago

Summit Therapeutics Raises $500 Million in Private Placement

Oct 20, 2025, 5:05 PM EDT - 4 months ago

Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call Transcript

Oct 20, 2025, 2:35 PM EDT - 4 months ago

Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold

Oct 20, 2025, 10:05 AM EDT - 4 months ago

What's Going On With Summit Therapeutics Stock On Monday?

Oct 20, 2025, 6:45 AM EDT - 4 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Oct 19, 2025, 10:30 AM EDT - 4 months ago

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Oct 17, 2025, 7:00 AM EDT - 4 months ago

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Oct 15, 2025, 7:00 AM EDT - 4 months ago

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Sep 24, 2025, 7:00 AM EDT - 5 months ago

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Sep 22, 2025, 2:45 PM EDT - 5 months ago

Ten Bull Market 10-Baggers

APP CVNA FTAI HOOD MSTR NVDA PLTR

Sep 17, 2025, 10:54 PM EDT - 5 months ago

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Sep 16, 2025, 4:31 PM EDT - 5 months ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 10, 2025, 12:43 AM EDT - 5 months ago

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 9, 2025, 9:12 AM EDT - 5 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

LNAI

Sep 8, 2025, 3:36 PM EDT - 5 months ago

Summit Therapeutics (SMMT) WCLC Update Call (Transcript)

Sep 8, 2025, 8:28 AM EDT - 5 months ago

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

Sep 8, 2025, 8:10 AM EDT - 5 months ago

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

NFE

Sep 7, 2025, 6:08 AM EDT - 5 months ago

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Sep 7, 2025, 3:30 AM EDT - 5 months ago

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Sep 3, 2025, 7:00 AM EDT - 5 months ago

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Aug 27, 2025, 2:43 PM EDT - 6 months ago

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Aug 14, 2025, 7:00 AM EDT - 6 months ago

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Aug 11, 2025, 5:03 PM EDT - 6 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Jul 14, 2025, 3:00 PM EDT - 7 months ago

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 4, 2025, 5:10 AM EDT - 8 months ago

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

AZN

Jun 30, 2025, 8:00 AM EDT - 8 months ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD

Jun 5, 2025, 8:00 AM EDT - 9 months ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 2, 2025, 2:52 PM EDT - 9 months ago

Summit Therapeutics: Market Overreaction Creates Opportunity

Jun 2, 2025, 9:10 AM EDT - 9 months ago

Is SMMT Stock A Buy After Its Recent Plunge?

May 30, 2025, 2:50 PM EDT - 9 months ago

Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release

May 30, 2025, 9:27 AM EDT - 9 months ago

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

May 30, 2025, 9:01 AM EDT - 9 months ago

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint